Browse
Submit Data
Databases
API
Help

Dataset Information

3 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase II study of a combination of CPT-11, 5FU/l-LV and UFT/LV in patients with advanced/recurrent colorectal cancer

ABSTRACT: Interventions: It takes 2 weeks for one course and that is to be repeated. Dose schedule for one course CPT-11 150mg/ m2/day Day 1 5-FU 500 mg/m2/day Day 1 l-LV 15 mg/m2/day Day 1 UFT 300 mg/m2/day Day 1-8 morning LV 75 mg/day Day 1-8 morning Primary outcome(s): response rate Study Design: Single arm Non-randomized

DISEASE(S): Advanced/recurrent Colorectal Cancer

PROVIDER: 2616118 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A Randomized Trial of Adjuvant Chemotherapy with UFT / LV versus PSK / UFT / LV following curative resection for Stage II / III Colorectal Cancer

Project description:Interventions: Group A (standard therapy group:UFT/LV 6M): Administration of 5 courses (6 months) of a schedule in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. Group B (trial therapy group: PSK/UFT/LV 6M): Administration of 5 courses (6 months) of a schedule in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. And administration of every day PSK (3g/body) for 6 months. Group C (trial therapy group: PSK/UFT/LV 12M): Administration of 10 courses (12 months) of a schedule in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. And administration of every day PSK (3g/body) for 12 months. Primary outcome(s): 3 year desease free survival rate Study Design: Parallel Randomized

| 2620921 | ecrin-mdr-crc

Phase III Comparative Clinical Trial of Treatment Schedules for Oral UFT/LV Therapy as Postoperative Adjuvant Chemotherapy for Stage IIB/III Colorectal Cancer

Project description:Interventions: Group A (standard therapy group): Administration of 5 courses (6 months) of a schedule (consecutive administration method) in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. Group B (trial therapy group): Administration of 15 courses (18 months) of a schedule (5 days on, 2 days off: Saturday and Sunday) in which one course consists of 5 weeks of UFT (300 mg/m2/day) and LV (75 mg/day) for 5 consecutive days followed by 2 days off. Primary outcome(s): disease-free survival Study Design: Parallel Randomized

| 2609649 | ecrin-mdr-crc

A randomized phase II study of UFT/LV or TEGAFOX for patient with curatively resected high risk Stage II and Stage III colorectal cancer.

Project description:Interventions: UFT(300mg/m2)+LV(75mg) /day, orally 4 weeks on and 1 week off in each corse. Total 5 weeks. UFT(300mg/m2)+LV(75mg) /day, orally 4 weeks on and 1 week off in each corse. Total 5 weeks. Oxaliplatin gives 85 mg/m2 intravenously on 1,15 day of each course. Primary outcome(s): 3-year desiese free survival rate Study Design: Parallel Randomized

| 2623111 | ecrin-mdr-crc

Phase II study of a combination of modified CPT-11 and 5-FU/l-LV (mJIFL) in patients with meatastatic colorectal cancer

Project description:Interventions: On Day 1, 8, 15, CPT-11 100 mg/m2 l-LV 250 mg/m2 administered simultaneously 5-FU 500 mg/m2 administered subsequently ** It takes 28 days for the one course. ** More than two courses are required. Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

| 2616231 | ecrin-mdr-crc

Randomized phase II study of mFOLFOX6 versus TS-1/CPT-11 in patients with advanced/recurrent colorectal cancer

Project description:Interventions: Group A:mFOLFOX6 Day 1 day 2 day 14 L-OHP 2HR l-LV 200mg/m2 5-FU 2,400mg/m2 civ 2HR 46HR ------------- | 5-FU 400mg/m2 iv Rapid Group B:TS-1/CPT-11 CPT-11 80 mg/m2CPT-11 80 mg/m2 1.5 hours 1.5 hours TS-1 40-60 mg/m2 | | | | Day 1 day 15 day 21 day 35 One course takes 35 days (5 weeks). Primary outcome(s): Response Rate(RECIST) Study Design: Parallel Randomized

| 2616289 | ecrin-mdr-crc

A feasibility study of adjuvant therapy with UFT/LV plus oxaliplatin following curative resection for stage III colorectal cancer

Project description:Interventions: UFT 300mg per m2 per day and LV 75mg per day for 28 days Oxaliplatin:85mg/m2 day1,15 every 5-weeks for 3-cycle After this therapy, followed by UFT/LV until 1 year Primary outcome(s): Patients ratio with completion of adjuvant TEGAFOX therapy Study Design: Single arm Non-randomized

| 2618840 | ecrin-mdr-crc

Phase II study of FOLFOX4 in patients with advanced/recurrent colorectal cancer previously treated with 5FU (OGSG 0503)

Project description:Interventions: FOLFOX 4 Treatment Day 1: 1. L-OHP 85mg/m2 is mixed with 250 cc of 5% glucose infusion.(A) 2. l-LV 100 mg/m2 is mixed with 250 cc of 5% glucose infusion.(B) 3. A and B are drip-infused by 2 hours using Y connection. 4. 5-FU 400mg/m2 is infused by 15 minutes, intravenously 5. 5-FU 600 mg/m2 is infused by 22 hours. Day 2: 1. l-LV 100mg/m2 is infused by 2 hours. 2. 5-FU 400 mg/m2 is infused by 15 minutes. 3. 5-FU 600 mg/m2 is infused by 22 hours Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

| 2616238 | ecrin-mdr-crc

Randomized phase II study with UFT capsule /LV or UFT E-granule /LV adjuvant chemotherapy for patients with completely resected high-risk stage II and III colorectal cancer

Project description:Interventions: UFT capsule / LV for 28 days with 7 days rest for 180days (6months)(1 course=5weeks, 35days). UFT E-granule / LV for 28 days with 7 days rest for 180days (6months)(1 course=5weeks, 35days). Primary outcome(s): treatment complete rate Study Design: Parallel Randomized

| 2626356 | ecrin-mdr-crc

Phase II study of first line chemotherapy with UFT/LV in elderly patients with advanced/recurrent colorectal cancer.

Project description:Interventions: UFT 300mg/m2/day and LV 75mg/body/day is administered orally for 28 days every 35 days. Primary outcome(s): response rate Study Design: Single arm Non-randomized

| 2622557 | ecrin-mdr-crc

Phase II study of chemotherapy with UFT/LV/Bevacizumab in elderly patients with advanced and recurrent colorectal cancer.

Project description:Interventions: UFT 300mg/m2/day and LV 50mg/body/day is administered orally for 21 days every 28 days. Bevacizumab 5mg/kg is administered intravenous injection on day 1,15. Primary outcome(s): Overall response rate Study Design: Single arm Non-randomized

| 2618906 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data